CRISPR Therapeutics
CRSP
CRSP
481 hedge funds and large institutions have $4.1B invested in CRISPR Therapeutics in 2024 Q1 according to their latest regulatory filings, with 74 funds opening new positions, 158 increasing their positions, 137 reducing their positions, and 56 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
15% more repeat investments, than reductions
Existing positions increased: 158 | Existing positions reduced: 137
2% more funds holding
Funds holding: 470 → 481 (+11)
0.23% less ownership
Funds ownership: 70.44% → 70.21% (-0.23%)
Holders
481
Holding in Top 10
5
Calls
$256M
Puts
$212M
Top Buyers
| 1 | +$116M | |
| 2 | +$94.7M | |
| 3 | +$71.5M | |
| 4 |
CIM
Contrarius Investment Management
St. Helier,
Jersey
|
+$32.9M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$28.6M |
Top Sellers
| 1 | -$61.8M | |
| 2 | -$46.5M | |
| 3 | -$25.8M | |
| 4 |
Jane Street
New York
|
-$20.4M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$19.1M |